Search by :
Explanation of HMSA's precertification process
|
|
On September 1, 2016, Medicare published an updated version of
its statutorily excluded Molecular Diagnostic (MolDx) tests. This
bulletin provides an explanation and instructions on how to access
this list.
|
|
Expanded collection sites now available for the H.pylori Breath
Test.
|
|
The Film Array Meningitis/Encephalitis Panel is an FDA approved,
comprehensive, multiplex molecular assay which accurately detects
multiple organisms, including viruses, all on a single, minimal
volume CSF specimen.
|
|
Beginning October 3, 2016, Kapiolani Medical Center for Women
and Children will offer the Respiratory Panel by PCR on site to
assist healthcare providers with faster diagnoses, improved
antibiotic stewardship and quicker results. This test will continue
to be offered at our reference lab as well.
|
|
Heparin Therapeutic Range will be adjusted effective September
26, 2016.
|
|
The Cepheid Xpert® MTB/RIF Direct PCR assay rapidly identifies
M. tuberculosis organisms, simultaneously detects
rifampin-resistant MTB, and aids in the decision of whether
continued airborne infection isolation is warranted for patients
with suspected pulmonary tuberculosis.
|
|
Test information for Hepatitis A Virus (HAV) available here.
|
|
The test name MICROALBUMIN, URINE RANDOM (code MAUR) will be
changed to ALBUMIN-TO-CREATININE RATIO (ACR), URINE. The test
code remains the same.
|
|
Clinical Labs of Hawaii has added the 1.8mL BD Vacutainer™ Plus
Plastic Citrate Tube to our supply list to allow for less
blood volume to be collected from patients helping with blood
utilization efforts, pediatric patients, and difficult collections
in elderly patients. Testing will be perfomed on both tube
types.
|
|